Takeda Pharmaceutical Co., and the Drugs for Neglected Diseases initiative announced they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL). The project has been selected…